Mohammed Kanjwal, MD
Cardiovascular Disease · Baltimore, MDNPI 1376537407
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,412 of the $10,702 with a category attached, or 69.3%. 33 manufacturers reported payments, led by Medtronic at 44.7% of the total. Reporting peaked in 2024 at $4,010 and has fallen 83.9% since, to $645 in 2025.
Across 246 payments — averaging $43.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Abbott$1K
- Boston Scientific$631
- Johnson & Johnson$606
- Biosense Webster, Inc.$581
- Medical Device Business Services, Inc.$488
- plus $3K from 27 others
Across 6 payments — averaging $779.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$5K
What the payments were for
- Travel & lodging$3,29031%
- Food & beverage$7,41269%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 71 | $4,788 |
| Abbott | 15 | $1,006 |
| Boston Scientific | 5 | $631 |
| Johnson & Johnson | 33 | $606 |
| Biosense Webster, Inc. | 8 | $581 |
| Medical Device Business Services, Inc. | 3 | $488 |
| Novartis | 17 | $283 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $275 |
| Kestra Medical Technology Services, Inc. | 4 | $263 |
| Edwards Lifesciences | 5 | $250 |
| Chiesi USA, Inc. | 14 | $217 |
| Pfizer | 12 | $201 |
| Inari Medical, Inc. | 2 | $189 |
| Stryker | 2 | $177 |
| Sanofi-aventis U.S. LLC | 2 | $104 |
| E.r. Squibb & Sons, L.L.C. | 6 | $77 |
| Biotronik Inc. | 4 | $71 |
| Baxter Healthcare | 3 | $54 |
| Atricure, Inc. | 1 | $53 |
| Lantheus Medical Imaging, Inc. | 3 | $52 |
| Novo Nordisk | 2 | $44 |
| Cardiva Medical, Inc. | 2 | $37 |
| Braemar Manufacturing, LLC | 1 | $34 |
| Innovation Technologies Inc | 1 | $30 |
| Irhythm Technologies, Inc. | 2 | $29 |
| AstraZeneca | 2 | $25 |
| Philips North America LLC | 1 | $24 |
| Merck | 1 | $22 |
| Merit Medical Systems Inc | 3 | $20 |
| Teleflex LLC | 1 | $19 |
| Cook Medical LLC | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Catheter Precision Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arctic Front$808
- Carto 3$795
- Reveal LINQ$220
- EVERA MRI XT DR SURESCAN$209
- Edwards SAPIEN 3 Transcatheter Heart Valve$162
- EnSite Precision Cardiac Mapping System$154
- ASSURITY$140
- PulseSelect$133
- Assure WCD$125
- FLOWTRIEVER CATHETER, S$125
- CT THROMBECTOMY SYSTEM KIT$125
- AMPLATZER AMULET$103
- FlowTriever$103
- TENDRIL$103
How this compares
$10,702 in reported general payments places this provider in the 85th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $36,342 |
| EntrestoSacubitril/Valsartan | 16 | $13,983 |
| Flecainide Acetate | 96 | $2,575 |
| Amiodarone Hcl | 29 | $540 |
| Metoprolol Succinate | 48 | $446 |
| Metoprolol Tartrate | 51 | $242 |
| Carvedilol | 12 | $217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $201 | $36,34226 claims |
| NovartisEntresto | $283 | $13,98316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Baltimore
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Charles CummingsBaltimore$114K
- John RickardBaltimore$109K
- Christopher DefilippiBaltimore$101K
- David KassBaltimore$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.